Jonathan Alicea


AKT1 E17K Mutation Targetable in Various Tumors Through AKT Inhibition

November 3rd 2017

A multihistology basket study proved the targetability of the AKT1 E17K mutation in human cancers by treating patients with various types of cancer harboring an AKT1 E17K mutation with AZD5363, an oral pan-AKT inhibitor,

Emerging Developments in CML

July 29th 2017

Kendra Sweet, MD, discusses the various factors that must be taken into account when prescribing first-line therapies to patients with CML, novel studies, and TKI discontinuation.

Therapeutic Options Developing for Non-Driver NSCLC, But Challenges Remain

July 27th 2017

Corey Langer, MD, discusses KEYNOTE-189, the current arena in NSCLC treatment, and the obstacles that remain in effectively treating patients with non-driver mutations.

Expert Discusses Latest Developments in MPNs

July 26th 2017

Rami Komrokji, MD, shares his insight on the various types of MPNs, how these diseases can be diagnosed and managed, and the next steps needed to improve patient outcomes.

Expert Highlights Advances for Patients With PNH

July 25th 2017

Mohamed Kharfan-Dabaja, MD, discusses the future of PNH treatment, the various symptoms that can present in PNH, and the challenges that still remain for further improving outcomes.

Expert Shares Optimism on Surgical Advances in Melanoma

July 24th 2017

Russell Berman, MD, discusses ongoing surgical advances in the treatment of melanoma.

Emerging Agents Poised to Transform AML Landscape

July 17th 2017

Jeffrey E. Lancet, MD, discusses new discoveries in the treatment of AML and challenges that remain in improving patient outcomes.

Proteasome Inhibitors Paving Promising Path for Myeloma Treatment

July 17th 2017

Kenneth H. Shain, MD, discusses the emergence of proteasome inhibitors in multiple myeloma and whether these agents will be best used as monotherapy or in combination regimens.